• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

News & Events

  • Print
  • Share
  • E-mail

Public Meeting on Economically Motivated Adulteration

May 1, 2009
9:00 a.m. - 5:00 p.m.
Harvey W. Wiley Federal Building
U.S. Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740-3835
Docket No: FDA-2009-N-0166


The U.S. Food and Drug Administration is announcing a Public Meeting pertaining to economically motivated adulteration (EMA). The purpose of the meeting is to stimulate and focus a discussion about ways in which the food, (including dietary supplements and animal food), drug, medical device and cosmetic industries, regulatory agencies, and other parties can better predict and prevent economically motivated adulteration. FDA invites interested individuals, organizations, and other stakeholders, including industry representatives, to present information pertaining to predicting and preventing EMA of food, (including dietary supplements and animal food), drugs, medical devices and cosmetics. The agency also requests interested parties to submit comments on this issue to the public docket.

For general questions about the meeting, to request on-site parking or for special accommodations due to a disability, contact: Juanita Yates, Center for Food Safety and Applied Nutrition, 301-436-1731, e-mail: juanita.yates@fda.hhs.gov.

Federal Register




The following slides will be available until June 3, 2009, at which time the FDA will provide a fully accessible version of the content or remove it from the site.

Addressing Challenges of Economically-Motivated Adulteration
Presenter: Randall Lutter, Ph.D., Deputy Commissioner for Policy, Food and Drug Administration
Text version

Defining Food Fraud & The Chemistry of the Crime 
Presenter: John Spink, Ph.D., Associate Director Anti-Counterfeiting and Product Protection Program (A-CAPPP), School of Criminal Justice

Economically Motivated Adulteration
Roger L. Williams, M.D., Chief Executive Officer Chair, Council of Experts, U.S. Pharmacopeia

Efforts to Ensure Excipient Safety
Irwin Silverstein, IPEC Americas, Inc.

Economically Motivated Adulteration 
Martin VanTrieste, Vice President Quality; Commercial Operations, Amgen

Summary of Comments: Economically Motivated Adulteration 
Lisa Weddig, National Fisheries Institute
Director, Regulatory and Technical Affairs
Secretary, Better Seafood Board

Suspected Economically Motivated Adulteration of FDA-Regulated Products 
John E. Bailey, Executive Vice President - Science Personal Care Products Council

Economically Motivated Adulteration 
Daniel Fabricant, Ph.D. Vice President, Scientific & Regulatory Affairs, Natural Products Association

Simple Authentication Methods for Herbal Ingredient Integrity in the face of EMA 
Steven Dentali, Ph.D., Chief Science Officer, American Herbal Products Association

Avoiding economic adulteration of dietary supplements: The need for ingredient supplier qualification guidelines
Andrew Shao, Ph.D., Vice President, Scientific & Regulatory Affairs, Council for Responsible Nutrition

Economically Motivated Adulteration in the Dietary Supplement Market Place 
William Obermeyer Ph.D., VP Research, ConsumerLab.com

Protecting Consumers from Adulterated Drugs 
Allan Coukell, Director, Pew Prescription Project, The Pew Charitable Trusts

Comments on Economically Motivated Adulteration
Xuman Amanda Tian, Research Associate, Food Safety Program, Center for Science in the Public Interest

Economically Motivated Adulteration 
Craig W. Henry Ph.D., Senior Vice President and Chief Operating Officer, Scientific and Regulatory Affairs
Grocery Manufacturers Association


Accessibility Information

Persons with disabilities having problems accessing the above ppt file may call Tina Gilliam, 301-827-7133 for assistance.